跳转至内容
Merck
  • Hypoxia-induced miR-210 in epithelial ovarian cancer enhances cancer cell viability via promoting proliferation and inhibiting apoptosis.

Hypoxia-induced miR-210 in epithelial ovarian cancer enhances cancer cell viability via promoting proliferation and inhibiting apoptosis.

International journal of oncology (2014-04-10)
Li'an Li, Ke Huang, Yanqin You, Xiaoyu Fu, Lingyun Hu, Lei Song, Yuanguang Meng
摘要

miR-210 is upregulated in a HIF-1α-dependent way in several types of cancers. In addition, upregulated miR-210 promotes cancer proliferation, via its anti-apoptotic effects. It is blind to the regulation of miR-210 under hypoxia conditions for ovarian cancer cells and to the effect of miR-210 on ovarian cancer growth. In the present study, we determined the expression of miR-210 in epithelial ovarian cancer specimens, and in ovarian cancer cell lines under hypoxia conditions, and determined in detail the effect of miR-210 overexpression on tumor cell proliferation, and the possible mechanisms of tumor growth by miR-210 regulation. It was shown that miR-210 expression is upregulated, in response to hypoxia conditions in epithelial ovarian cancer specimens as well as epithelial ovarian cancer cell lines, with an association to HIF-1α overexpression. Furthermore, upregulated miR-210 promoted tumor growth in vitro via targeting PTPN1 and inhibiting apoptosis. Therefore, our findings shed light on the mechanism of ovarian cancer adaptation to hypoxia.

材料
货号
品牌
产品描述

Sigma-Aldrich
碘化丙啶, ≥94.0% (HPLC)
Sigma-Aldrich
5-氟脲嘧啶, ≥99% (HPLC), powder
Sigma-Aldrich
碘化丙啶 溶液
Sigma-Aldrich
碘化丙啶, ≥94% (HPLC)
USP
氟脲嘧啶, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
氟脲嘧啶, meets USP testing specifications
Supelco
氟尿嘧啶, Pharmaceutical Secondary Standard; Certified Reference Material
Supelco
5-氟脲嘧啶, analytical standard
氟尿嘧啶, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
Monoclonal Anti-CASP9 antibody produced in mouse, clone 3B8-4G2, purified immunoglobulin, buffered aqueous solution